Diligence memo · auto-generated · as of July 3, 2026

Skincure Oncology Llc

Skincure Oncology Llc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Skincure Oncology Llc operates in Pharma, based in Burr Ridge.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Skincure Oncology Llc has raised $33M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $30M on 2019-07-18.

Most recent recorded round closed around 2019-07-18.

Valuation (modeled)modeled

Provath models Skincure Oncology Llc at approximately $1.0B (range $63M–$3.9B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.42× the median modeled value of Series B Pharma companies in 2019–2021 (8 peers) — value vs value, same stage and era. Within the normal band (142% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 11 months.

Last raise 7.0 yr ago; this sector typically re-raises about every 16 months.

Silent for over 3× the sector's normal cadence.

The last round stepped up 42.3× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 82% of Pharma peers (310 compared).

Modeled value ranks above 91% of those peers.

Closest niche peers: Rescale, Inc., Small Pharma Financing Inc., Oncology Analytics, Inc., Pasithea Therapeutics Corp., Kwivik Therapeutics, Inc..

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.